共 50 条
- [21] Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantationAnnals of Hematology, 1999, 78 : 380 - 384F. FerraraL. MelilloM. MontilloF. LeoniA. PintoG. MeleS. Mirto
- [22] A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaAnnals of Hematology, 2018, 97 : 763 - 772David Martínez-CuadrónBlanca BoludaPilar MartínezJuan BerguaRebeca Rodríguez-VeigaJordi EsteveSusana VivesJosefina SerranoBelen VidrialesOlga SalameroLourdes CordónAmparo SempereAna Jiménez-UbietoJulio Prieto-DelgadoMarina Díaz-BeyáAna GarridoCelina BenaventeJosé Antonio Pérez-SimónFederico MoscardóMiguel A. SanzPau Montesinos
- [23] Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse-risk acute myeloid leukaemia: A single-centre retrospective analysisEJHAEM, 2023, 4 (04): : 1208 - 1211Song, Bao-QuanKong, XinPu, YanLiu, YinZhang, JianWu, De-PeiQiu, Hui-Ying
- [24] Advances in treatment of de-novo pediatric acute myeloid leukemiaCURRENT OPINION IN ONCOLOGY, 2014, 26 (06) : 656 - 662Ribeiro, Raul C.
- [25] Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective studyANNALS OF HEMATOLOGY, 2024, : 5315 - 5323Ma, HongbingDu, YiwenLi, JianjunRao, JinGuo, YongYang, YunfanZhang, DuanzhongWang, JiaLiao, YiGong, Yuping
- [26] Efficacy and safety evaluation of Venetoclax combined with homoharringtonine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemiaPANMINERVA MEDICA, 2024,Wei, MingxiaShen, XuliangZhai, ChunyanGao, Wenyu
- [27] A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naive Acute Myeloid LeukemiaBLOOD, 2022, 140 : 6213 - 6214Jonas, Brian A.Welborn, Jeanna L.Esteghamat, Naseem S.Hoeg, Rasmus T.Rosenberg, Aaron S.Molnar, LauraDang-Chu, Ashley LinhStewart, Susan L.Tuscano, Joseph M.
- [28] A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaANNALS OF HEMATOLOGY, 2018, 97 (05) : 763 - 772Martinez-Cuadron, DavidBoluda, BlancaMartinez, PilarBergua, JuanRodriguez-Veiga, RebecaEsteve, JordiVives, SusanaSerrano, JosefinaVidriales, BelenSalamero, OlgaCordon, LourdesSempere, AmparoJimenez-Ubieto, AnaPrieto-Delgado, JulioDiaz-Beya, MarinaGarrido, AnaBenavente, CelinaAntonio Perez-Simon, JoseMoscardo, FedericoSanz, Miguel A.Montesinos, Pau
- [29] Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaAnnals of Hematology, 2018, 97 : 923 - 923David Martínez-CuadrónBlanca BoludaPilar MartínezJuan BerguaRebeca Rodríguez-VeigaJordi EsteveSusana VivesJosefina SerranoBelen VidrialesOlga SalameroLourdes CordónAmparo SempereAna Jiménez-UbietoJulio Prieto-DelgadoMarina Díaz-BeyáAna GarridoCelina BenaventeJosé Antonio Pérez-SimónFederico MoscardóMiguel A. SanzPau Montesinos
- [30] Phase I Trial Combining Venetoclax with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients with High-Grade Myeloid NeoplasmsBLOOD, 2023, 142Raychaudhuri, SuraviGooley, TedGill, ZachRasmussen, AllegraHalpern, Anna B.Appelbaum, Jacob S.Ghiuzeli, Cristina MariaHendrie, Paul C.Cassaday, Ryan D.Walter, Roland B.Estey, ElihuPercival, Mary-Elizabeth M.